A PHASE-II STUDY OF ANTITUMOR EFFICACY AND SAFETY OF EXEMESTANE (EXE)AS 3RD-LINE HORMONAL TREATMENT OF POSTMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER (MBC) REFRACTORY TO TAMOXIFEN AND MEGACE(TM)
S. Jones et al., A PHASE-II STUDY OF ANTITUMOR EFFICACY AND SAFETY OF EXEMESTANE (EXE)AS 3RD-LINE HORMONAL TREATMENT OF POSTMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER (MBC) REFRACTORY TO TAMOXIFEN AND MEGACE(TM), Annals of oncology, 9, 1998, pp. 64-64